DE602005020618D1 - Verwendung von neboglamine zur behandlung von schizophrenie - Google Patents

Verwendung von neboglamine zur behandlung von schizophrenie

Info

Publication number
DE602005020618D1
DE602005020618D1 DE602005020618T DE602005020618T DE602005020618D1 DE 602005020618 D1 DE602005020618 D1 DE 602005020618D1 DE 602005020618 T DE602005020618 T DE 602005020618T DE 602005020618 T DE602005020618 T DE 602005020618T DE 602005020618 D1 DE602005020618 D1 DE 602005020618D1
Authority
DE
Germany
Prior art keywords
neboglamine
schizophrenia
treatment
dimethylcyclohexyl
racemate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005020618T
Other languages
English (en)
Inventor
Francesco Makovec
Lucio Claudio Rovati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rottapharm SpA
Original Assignee
Rottapharm SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm SpA filed Critical Rottapharm SpA
Publication of DE602005020618D1 publication Critical patent/DE602005020618D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE602005020618T 2004-05-24 2005-05-23 Verwendung von neboglamine zur behandlung von schizophrenie Active DE602005020618D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000343A ITTO20040343A1 (it) 2004-05-24 2004-05-24 Uso di neboglamine (cr2249) come neuropsicotico e neuroprotettivo
PCT/EP2005/052340 WO2005115373A1 (en) 2004-05-24 2005-05-23 Use of neboglamine (cr 2249) as an antipsychotic and neuroprotective

Publications (1)

Publication Number Publication Date
DE602005020618D1 true DE602005020618D1 (de) 2010-05-27

Family

ID=34968609

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005020618T Active DE602005020618D1 (de) 2004-05-24 2005-05-23 Verwendung von neboglamine zur behandlung von schizophrenie

Country Status (13)

Country Link
US (1) US7737180B2 (de)
EP (1) EP1755583B1 (de)
JP (1) JP4898666B2 (de)
AT (1) ATE464042T1 (de)
AU (1) AU2005247114B2 (de)
CA (1) CA2567397C (de)
DE (1) DE602005020618D1 (de)
DK (1) DK1755583T3 (de)
ES (1) ES2340399T3 (de)
IT (1) ITTO20040343A1 (de)
PL (1) PL1755583T3 (de)
PT (1) PT1755583E (de)
WO (1) WO2005115373A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20050691A1 (it) * 2005-10-04 2007-04-05 Rottapharm Spa Uso di neboglamine nella terapia delle tossicodipendenze

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1931927A1 (de) 1968-07-06 1970-01-15 Yamanouchi Pharma Co Ltd Neue Cyclohexylaminderivate
IT1264765B1 (it) * 1993-03-10 1996-10-04 Rotta Research Lab Derivati dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso come farmaci potenzianti la
AR037460A1 (es) * 2001-11-30 2004-11-10 Smithkline Beecham Plc Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion

Also Published As

Publication number Publication date
DK1755583T3 (da) 2010-07-19
CA2567397C (en) 2013-03-12
AU2005247114A1 (en) 2005-12-08
PL1755583T3 (pl) 2010-09-30
JP2008500309A (ja) 2008-01-10
CA2567397A1 (en) 2005-12-08
JP4898666B2 (ja) 2012-03-21
US7737180B2 (en) 2010-06-15
ATE464042T1 (de) 2010-04-15
EP1755583A1 (de) 2007-02-28
AU2005247114B2 (en) 2010-06-03
EP1755583B1 (de) 2010-04-14
ES2340399T3 (es) 2010-06-02
US20070249715A1 (en) 2007-10-25
WO2005115373A1 (en) 2005-12-08
ITTO20040343A1 (it) 2004-08-24
PT1755583E (pt) 2010-05-07

Similar Documents

Publication Publication Date Title
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60324180D1 (de) Behandlung der huntington's krankheit mit epa
ATE469674T1 (de) 5-aminolävulinsäure-derivate zur behandlung von akne
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
DE602006003415D1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
EA200701615A1 (ru) Новые лекарственные средства для лечения заболеваний дыхательных путей
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
EA200600833A1 (ru) Тиазолидиноны, их получение и применение как фармацевтических агентов
MY148683A (en) Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
DE602005017629D1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
MA27649A1 (fr) Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci.
DE602005020618D1 (de) Verwendung von neboglamine zur behandlung von schizophrenie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition